A 52-year-old man from Delhi presents with a 3-month history of polyuria, polydipsia, and weight loss of 4 kg. He is a known hypertensive on amlodipine. On examination, BMI is 28 kg/m², blood pressure 138/88 mmHg. Fasting blood glucose is 156 mg/dL, postprandial glucose 248 mg/dL, and HbA1c is 8.2%. Renal function and liver function tests are normal. He is started on metformin 500 mg twice daily with dietary modifications. After 6 weeks, fasting glucose is 132 mg/dL and postprandial glucose is 210 mg/dL. His HbA1c remains 8.1%. What is the most appropriate next step in pharmacological management?

Explanation

## Clinical Assessment This patient has newly diagnosed type 2 diabetes mellitus with inadequate glycemic control on monotherapy with metformin at a suboptimal dose. ### Current Status - **Baseline HbA1c:** 8.2% (diagnostic for diabetes) - **After 6 weeks metformin 500 mg BD:** HbA1c 8.1% (minimal improvement) - **Fasting glucose:** Still 132 mg/dL (target <130 mg/dL) - **Postprandial glucose:** 210 mg/dL (target <180 mg/dL) - **Renal function:** Normal (eGFR not stated but implied normal) ### Rationale for Sulfonylurea Addition **Key Point:** When monotherapy with metformin fails to achieve glycemic targets within 3 months, a second agent should be added. Sulfonylureas remain first-line dual therapy agents in resource-limited settings and are highly effective. **High-Yield:** The patient's metformin dose (500 mg BD = 1000 mg/day) is subtherapeutic. However, the question asks for the "next step" after 6 weeks of therapy—at this point, rather than titrating metformin further (which would delay dual therapy), adding a second agent is more appropriate per ADA/EASD consensus and Indian guidelines. **Clinical Pearl:** Gliclazide is a meglitinide-like sulfonylurea with rapid onset and short duration, making it ideal for postprandial hyperglycemia control. Starting dose of 80 mg once daily is standard in India. ### Why This Patient Needs Dual Therapy Now - HbA1c reduction of only 0.1% over 6 weeks suggests inadequate monotherapy response - Persistent fasting and postprandial hyperglycemia despite dietary intervention - No contraindications to sulfonylurea (normal renal/hepatic function, no hypoglycemia unawareness) ## Comparison of Options | Intervention | Rationale | Limitation | |---|---|---| | **Increase metformin to 1000 mg BD** | Dose optimization is reasonable, but delays dual therapy initiation | Monotherapy unlikely to achieve target; GI side effects risk | | **Add sulfonylurea (gliclazide)** | **CORRECT** — Proven efficacy, cost-effective, rapid onset, addresses both fasting and postprandial glucose | Minor hypoglycemia risk; weight gain | | **Add DPP-4 inhibitor** | Neutral glycemic effect, weight-neutral, safe; but less potent than sulfonylurea for this degree of hyperglycemia | More expensive; reserved for second-line in resource-limited settings | | **Start insulin** | Premature; insulin is indicated after failure of oral dual/triple therapy | Requires injection, patient education, hypoglycemia monitoring | **Mnemonic:** **METPLUS** — **MET**formin + **PLUS** one agent for inadequate control: - **S**ulfonylurea (first-line dual agent, potent) - **D**PP-4 inhibitor (weight-neutral, safe) - **T**hiazolidinedione (insulin-sensitizer) - **G**LP-1 agonist (weight loss, cardioprotection) - **I**nsulin (last resort) [cite:KD Tripathi 8e Ch 28]